Clinical Trial

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a variety of solid tumors, including small cell lung cancer, multiple myeloma, and neuroblastoma, and hematological malignancies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-15; most recent amendment 2026-06-17.
Status change: Not Yet Recruiting → Recruiting 2025-01-26
Trial Details
NCT Number NCT06224855
Lead Sponsor Hangzhou DAC Biotechnology Co., Ltd.
Conditions Advanced Solid Tumors, Hematological Malignancies
Enrollment 280 participants
Start Date 2024-01-24
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22